Sigyn Therapeutics (SIGY) Gross Margin (2017 - 2020)
Sigyn Therapeutics (SIGY) posted Gross Margin of 53.08% for Q3 2020, down 18.61% sequentially from 65.21% in Q1 2020, and down 2197.0% YoY from 2.53% in Q4 2019.
Sigyn Therapeutics (SIGY) Gross Margin (2017 - 2020) Analysis & Trends
Sigyn Therapeutics has reported Gross Margin for 4 years, with the latest figure at 53.08% in Q3 2020.
- Quarterly Gross Margin fell 2197.0% year-over-year to 53.08% in Q3 2020, while the trailing twelve-month figure through Sep 2020 was 63.37% (up 23239.0% YoY) and the FY2019 annual result came in at 75.12%, up 938.0% from the prior year.
- Gross Margin eased to 53.08% in Q3 2020 per SIGY's latest filing, from 65.21% in the prior quarter.
- Over five years, Gross Margin peaked at 33711600.0% in Q4 2018 and troughed at 18.11% in Q4 2017.
- A 4-year average of 2408147.84% and a median of 71.12% in 2019 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2018 and 2019: Gross Margin soared 2000000000 bps in 2018, then plunged 2000000000 bps in 2019.
- Over 4 years, Gross Margin stood at 18.11% in 2017, then jumped by 186171051 bps to 33711600.0% in 2018, then tumbled by 100 bps to 70.5% in 2019, then retreated by 25 bps to 53.08% in 2020.
- According to Business Quant data, Gross Margin over the past three periods registered 53.08%, 65.21%, and 70.5% for Q3 2020, Q1 2020, and Q4 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 76.90% |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 63.27% |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 84.20% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 53.08% |
| Mar 31, 2020 | 65.21% |
| Dec 31, 2019 | 70.50% |
| Sep 30, 2019 | 75.05% |
| Jun 30, 2019 | 73.84% |
| Mar 31, 2019 | 77.74% |
| Dec 31, 2018 | 33,711,600.00% |
| Sep 30, 2018 | 87.94% |
| Jun 30, 2018 | 1,735.84% |
| Mar 31, 2018 | 58.18% |
| Dec 31, 2017 | -18.11% |
| Sep 30, 2017 | 61.53% |
| Jun 30, 2017 | 57.17% |
| Mar 31, 2017 | 71.74% |